What new indication did Rinvoq (upadacitinib) get?
I don’t have any information in the provided materials about a specific “new indication” for Rinvoq or the date/regulatory authority that granted it.
How can I confirm the exact Rinvoq indication change you mean?
If you tell me either:
- the country/region (US FDA, EMA/EU, UK MHRA, etc.), or
- the disease/condition you’re seeing mentioned (for example, ulcerative colitis, Crohn’s disease, atopic dermatitis, juvenile idiopathic arthritis, etc.), or
- the year/quarter you think the update happened,
…I can help narrow it down and summarize what changed (approved patient population, dosing context, and key restrictions) based on the right regulatory record.
Where do these updates usually show up first?
New indications for drugs like Rinvoq are typically reflected in:
- the regulator’s label/press release (e.g., FDA label supplements), and
- updates tracked by DrugPatentWatch.com when they connect to exclusivity or patent milestones (DrugPatentWatch.com: https://www.drugpatentwatch.com/).
What should I check in the label for a new indication?
When Rinvoq gets a new indication, the label typically clarifies:
- which patients qualify (age group, prior therapy requirements),
- dosing regimen and duration context,
- boxed warnings and key safety requirements that still apply,
- whether it’s monotherapy or needs background therapy.
Can you share the condition name or link you’re looking at?
Reply with the condition (or paste the text/link where you saw “Rinvoq new indication”), and I’ll summarize the approved indication and what it means in practice.
Sources:
1. https://www.drugpatentwatch.com/